1. "GSK Faculty"
Formats
  1. Journal Article (13834)
  2. Meeting Abstract (7076)
  3. Review (514)
  4. Book Section (342)
  5. Editorial (307)
  6. Conference Paper (162)
  7. Research Letter (96)
  8. Miscellaneous (45)
  9. Correspondence (38)
  10. Guidelines (32)
  11. Book Whole (22)
Groups
  1. GSK Faculty (22468)
  2. Sloan Kettering Institute Faculty (11482)
  3. Department of Medicine (10529)
  4. Tow Center for Developmental Oncology (TCDO) (6948)
  5. Sloan Kettering Institute Postdocs (6210)
  6. Solid Tumor Oncology Division (5880)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Steven Larson (957)
  3. Jedd Wolchok (905)
  4. Cristina Antonescu (895)
  5. Kenneth Offit (788)
  6. David Solit (779)

More People

Years
  1. 2025 (296)
  2. 2024 (868)
  3. 2023 (1016)
  4. 2022 (1152)
  5. 2021 (1088)
  6. 2020 (1257)

More Years

Publications
  1. Blood (1470)
  2. Journal of Clinical Oncology (1279)
  3. Cancer Research (1104)
  4. Clinical Cancer Research (527)
  5. Modern Pathology (494)
  6. Journal of Nuclear Medicine (474)

More Publications

Publishers
  1. Nature Publishing Group (2594)
  2. American Association for Cancer Research (2194)
  3. Elsevier Inc. (1937)
  4. American Society of Hematology (1553)
  5. Cell Press (1421)
  6. American Society of Clinical Oncology (1379)

More Publishers

Results (22468)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A WIMSical approach to decoding DNA methylation in myeloid leukemia
    Journal Article

    Guryanova, O. A.; Levine, R. L.
    Genome Biology (2014)

    Fulltext@MSK | Save
  • Global challenges in oncologic imaging
    Journal Article

    Hricak, H.
    Cancer Imaging (2014)

    Fulltext@MSK | Save
  • Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus
    Meeting Abstract

    Zamarin, D.; Holmgaard, R. B.; Subudhi, S. K.; Park, J. S.; Mansour, M.; Palese, P.; Merghoub, T.; Wolchok, J. D.; Allison, J. P.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma
    Meeting Abstract

    Wen, P. Y.; Yung, W. K. A.; Mellinghoff, I. K.; Ramkissoon, S.; Alexander, B. M.; Rinne, M. L.; Colman, H.; Omura, A. M. P.; Deangelis, L. M.; Gilbert, M. R.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Establishing a neoadjuvant platform for developing targeted agents: Degarelix prior to prostatectomy for patients with intermediate- and high-risk prostate cancer
    Meeting Abstract

    Touijer, K. A.; Carver, B. S.; Coleman, J. A.; Laudone, V. P.; Hullings, M.; Ehrlich, S. S.; DeNunzio, M.; Reuter, V. E.; Eastham, J. A.; Danila, D. C.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Predictors of overall survival in patients diagnosed with desmoplastic small round cell tumor (DSRCT)
    Meeting Abstract

    Shoushtari, A. N.; Qin, L. X.; Kuk, D.; Magnan, H. D.; Modak, S.; Wolden, S. L.; Cho, E. J.; Pallos, V.; Grubman, O.; Viny, A. D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors
    Meeting Abstract

    Segal, N. H.; Hodi, F. S.; Sanborn, R. E.; Gajewski, T.; Wolchok, J. D.; Urba, W. J.; Fox, B. A.; Topallan, S. L.; Pardoll, D. M.; Kollia, G.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab
    Meeting Abstract

    Schindler, K.; Harmankaya, K.; Kuk, D.; Mangana, J.; Michielin, O.; Hoeller, C.; Dummer, R.; Pehamberger, H.; Wolchok, J. D.; Postow, M. A.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save